




# Abstract Poster Quick Guide

**2025 NANETS  
Multidisciplinary NET  
Medical Symposium**

**NANETS** 

# POSTER HALL MAP



**2025 NANETS**  
**Multidisciplinary NET**  
**Medical Symposium**

## Category 1: Basic Science

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
B-1	Spatial and Transcriptional Profiling Reveals Immune Remodeling and Microenvironmental Heterogeneity in Benign and Malignant Pancreatic Neuroendocrine Tumors	Gareth Pollin	PhD	Medical College of Wisconsin	33416
B-2	Validation of Adversity-Linked Genes in Pancreatic Neuroendocrine Tumors	Andrea Gillis	MD	University of Alabama at Birmingham	33478
B-3	A SST14 based T-cell engager for the treatment of neuroendocrine tumors	Eleonora Pelle	MD	Moffitt Cancer Center	33480
B-4	Single-nucleus transcriptomic analysis of the tumor microenvironment in small intestinal NETs	Netta Mäkinen	PhD	Dana-Farber Cancer Institute	33446
B-5	Uncovering Filamin A as an Exosomal Biomarker in PanNET Through Integrative Tissue Proteomics	Priya Gorai	PhD	All India Institute of Medical Sciences, New Delhi, India	33394
B-6	Tumor-Intrinsic Adaptations to Liver Microenvironment Drive Metastasis in Pancreatic and Small Intestinal Neuroendocrine Tumors	James Madigan	PhD	National Cancer Institute, NIH	33444
B-7	Changes in the Tumor Microenvironment of Well-Differentiated Metastatic Neuroendocrine Tumors might mediate resistance in patients treated with 177Lu-DOTATATE	Rahil Abbu	MSc	UChicago Medicine	33448
B-8	Deciphering the Functionality of MAX Phosphorylation Dynamics in Pancreatic Neuroendocrine Tumors	Theo Hines		University of Alabama At Birmingham	33449
B-9	Spatial Transcriptomics Reveals Local Subtype-Specific Identity and Signaling within Multifocal Small Intestinal Neuroendocrine Tumors	Akitada Yogo	PhD	University of California, San Francisco	33417
B-10	Allosteric ClpP agonist ONC206 alters mitochondrial metabolism, stress response and chromatin accessibility to elicit apoptosis in pheochromocytoma	Meghan Sullivan	PhD, CMPP	Chimerix, Inc	33451

## Category 2: Applied Basic Science

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
B-11	Mechanisms and Models for Cdk5 dependent Neuroendocrine Tumors	Kylie Dickerson	MD	University of Arizona Phoenix	33398
B-12	Influence of patient cohort size on PFS prediction accuracy using baseline SSTR image models	Victor Santoro Fernades	PhD	University of Wisconsin-Madison	33461
B-13	Claudin 18.2 in pancreatic neuroendocrine tumors: a potential therapeutic target	Garima Gupta	MD	O'Neal Cancer Center at University of Alabama at Birmingham	33488
B-14	Advanced 3D preclinical models of pancreatic neuroendocrine tumors: from bioprinting to precision-cut tumor slices	Stefano Partelli	MD, PhD	IRCCS San Raffaele Institute	33407

## Category 3: Chemo/SSA/Biologics (Clinical)

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
C-1	An ongoing phase 1 trial of obixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression	Jaume Capdevila Castillon	MD, PhD	Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology	33400
C-2	Prognostic Significance of MEN1, ATRX, and DAXX Mutations in Pancreatic Neuroendocrine Tumors Treated with CAPTEM: Insights from a Multicenter Cohort	Chirayu Mohindroo	MD	Sinai Hospital of Baltimore	33482
C-3	Investigator-Assessed Disease Progression in a Phase 2 Study of Paltusotine in Patients with Neuroendocrine Tumors and Carcinoid Syndrome	Amr Mohamed	MD	University Hospitals Seidman Cancer Center, Case Western Reserve University	33401

### Category 3: Chemo/SSA/Biologics (Clinical)

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
C-4	Multicenter Real-World Study of Treatment Patterns in Well-Differentiated Grade 3 (G3) Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	Angelo Pirozzi	MD	Mayo Clinic Arizona	33418
C-5	PPM1D as a Potential Driver of Myeloid Malignancy Transformation in Neuroendocrine Tumor (NET) Pts: An Underrecognized Malignant CHIPerpetrator?	Abhay Singh	MD, MPH	Cleveland Clinic	33455
C-6	TROP2 Expression in the Gastroenteropancreatic Neuroendocrine Tumors; An analysis of 179 patients	Junaid Arshad	MD, MS	University of Arizona	33192
C-7	The Hidden Cost of Enzyme Therapy: Oxalate Nephropathy in a NET Patient with Pancreatic Insufficiency	Thorvardur Halfdanarson	MD	Mayo Clinic	33387
C-8	DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomas	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33390
C-9	Somatic genomic profiling of gastrointestinal neuroendocrine tumors: Implications for prognostication and therapeutic targeting	Chirayu Mohindroo	MD	Sinai Hospital of Baltimore	33415
C-10	The Efficacy of Low-dose vs Standard-dose Everolimus in Patients with Advanced Neuroendocrine Tumors	Oudai Sahwan	MBBS	Mayo Clinic	33441
C-11	The useful combination of capecitabine and temozolomide (CAPTEM) in metastatic lung carcinoid tumors	Amanda Cass	PharmD	Vanderbilt University Medical Center	33476

## Category 4: Nuclear Medicine/Interventional Radiology/Imaging (Clinical)

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
C-12	Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET)	Michael Soulen	MD, FSIR, FCIRSE	Abramson Cancer Center University of Pennsylvania	33254
C-13	Safety and clinical implications of concurrent biopsy of neuroendocrine liver metastases at the time of liver-directed therapy	Rosa Thuemmler	MBChB	Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen UK	33410
C-14	Efficacy of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses)	Jaume Capdevila Castillon	MD, PhD	Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology	33388
C-15	Long-term Follow-up of PRRT-Naïve Patients with GEP-NETs Treated with Targeted Alpha Therapy 212Pb-DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial	Mary Maluccio	MD, MPH, FACS	LSU School of Medicine	33414
C-16	Phase 2 Study of Targeted Alpha Therapy 212Pb-DOTAMTATE in Patients with Advanced Gastroenteropancreatic (GEP)-NETs Previously Treated with PRRT	Jonathan Strosberg	MD	Moffitt Cancer Center	33429
C-17	61Cu-NODAGA-LM3 versus 68Ga-DOTATOC in the same patients with neuroendocrine tumors: Preliminary results of the Phase I/II COPPER-PET-in-NET Trial	Guillaume Nicolas	MD	University of Basel	33431
C-18	Patient Characteristics and Treatment Patterns With [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) In the US: A Real-World Assessment	Anteneh Tesfaye	MD	Novartis Pharmaceutical Corp	33412

## Category 4: Nuclear Medicine/Interventional Radiology/Imaging (Clinical)

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
C-19	[ <sup>212</sup> Pb]VMT-alpha-NET for advanced SSTR+ NETs: safety and preliminary efficacy results from cohorts 1 and 2 of the dose escalation phase	Thorvardur Halfdanarson	MD	Mayo Clinic	33440
C-20	Multi-center NCI-sponsored phase 1 study of triapine in combination with <sup>177</sup> Lu-dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33403
C-21	Single institution experience with [ <sup>131</sup> I]MIBG for pheochromocytoma and paraganglioma: Long-term outcomes and dosimetry	Razan Ali	BS	Washington State University College of Medicine	33501
C-22	Systematic Literature Review and Radiomics Quality Assessment for Lung, Adrenal, Thyroid and Pituitary Neuroendocrine Tumors	Praval Ghanta	dBSd	Moffitt Cancer Center	33190
C-23	Efficacy and safety of [ <sup>177</sup> Lu]Lu-edotreotide ([ <sup>177</sup> Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors (NETs) – a systematic literature review (SLR) and meta-analysis	Julia Fricke	MD	University Hospital Basel	33271
C-24	First-line Treatment with [ <sup>177</sup> Lu]Lu-edotreotide ([ <sup>177</sup> Lu]Lu-DOTATOC) in patients with NETs: a SwissNET Registry Analysis	Guillaume Nicolas	MD	University of Basel	33277
C-25	Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease	Nicholas Fidelman	MD	University of California San Francisco	33393
C-26	Clinical outcomes following salvage PRRT in patients with metastatic neuroendocrine tumors	Regina Koch	MD	Mayo Clinic	33402

## Category 4: Nuclear Medicine/Interventional Radiology/Imaging (Clinical)

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
C-27	Efficacy and Safety of Peptide Receptor Radionuclide Therapy Retreatment (r-PRRT) Practices in Progressive Neuroendocrine Tumors (prog-NETs): Systematic Review and Meta-Analysis	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33411
C-29	Correlation of dosimetry and toxicity for Lu177-DOTATATE in GEP-NETs	Erik Mittra	MD, PhD	Oregon Health & Science University	33437
C-30	DISCO: Safety, Tolerability and Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors.	Erica Sztangret	PharmD	Clarity Pharmaceuticals	33463
C-32	Incidence of Peripheral Inserted Central Line Complications with Administration of 177Lutetium Dotatate	Amanda Cass	PharmD	Vanderbilt University Medical Center	33479
C-33	Somatostatin receptor expression on 68Ga-Dotatate imaging among patients with poorly differentiated extra-pulmonary neuroendocrine carcinomas: a prospective study	Taymeyah Al-Toubah	MPH	H. Lee Moffitt Cancer Center and Research Institute	33491
C-34	Outcomes of Peptide Receptor Radionuclide Therapy in Patients with Pheochromocytoma and Paraganglioma: A Center of Excellence Experience	Matthew Gao	BS	University of Iowa Carver College of Medicine	33493

## Category 5: Surgery/Applied Pathology (Clinical)

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
C-35	Care of Neuroendocrine Tumors: the Collaborative of sUrgical Teams for NeuroEndocrine Tumors (CUTNETs)	Julie Hallet	MD, MSc, FRCSC, FSSO	University of Toronto	32944
C-36	The Natural History of Small Bowel Neuroendocrine Tumor (SBNET) Metastases.	Jeremy Chang	MS, MD	University of Iowa Hospitals and Clinics	33395
C-37	International expert consensus on perioperative management of carcinoid crisis.	Julie Hallet	MD, MSc, FRCSC, FSSO	University of Toronto	32914
C-38	Association of Surgical Intervention with 30-Day Re-admission and Outcomes in Patients Hospitalized for Small Bowel Neuroendocrine Tumor-Related Obstruction	Raj Shah	MD	University of Kansas-Wichita	33000
C-39	Primary Tumor Resection Is Associated With Improved Survival in Metastatic GI-NETs: A Retrospective Study in the Bronx, NY	Bahar Laderian	MD	Montefiore Einstein Comprehensive Cancer Center, Montefiore Medical Center, Albert Einstein College of Medicine	33471
C-40	Short-term post-operative outcomes after surgery for entero-pancreatic neuroendocrine tumors (NETs): a population-based analysis.	Julie Hallet	MD, MSc, FRCSC, FSSO	University of Toronto	32943
C-41	Survival outcomes after surgery for entero-pancreatic neuroendocrine tumors: a population-based analysis.	Julie Hallet	MD, MSc, FRCSC, FSSO	University of Toronto	28492
C-42	Risk Factors and Prognosis of Peritoneal Metastases in Small Bowel Neuroendocrine Tumor Patients	Jeremy Chang	MS, MD	University of Iowa Hospitals and Clinics	33396
C-43	Mapping the evidence for surgical care of gastro-entero-pancreatic neuroendocrine tumors: a scoping review.	Julie Hallet	MD, MSc, FRCSC, FSSO	University of Toronto	33439

## Category 5: Surgery/Applied Pathology (Clinical)

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
C-44	Resection of Primary Pancreatic Neuroendocrine Tumors in the Metastatic Setting	Sarah Wornow	BS	Perelman School of Medicine, University of Pennsylvania	33454
C-45	Improving Outcomes for Neuroendocrine Patients: 25 year review of 1699 NET Surgical Cytoreduction Patients at a Single Institution	Sanchit Sachdeva	MD	Louisiana State University Health Science Center	33458
C-46	Evaluating the role of postoperative long-acting somatostatin analogue therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking	Theodoros Michelakos	MD	University of Chicago	33474
C-47	Role of Surgery in Patients with G1-G2 Pancreatic Neuroendocrine Tumors and Synchronous Liver Metastases	Valentina Andreasi	MD, PhD	San Raffaele Scientific Institute	33475
C-48	Pancreatic Neuroendocrine Tumors with Intraductal Growth: Unraveling a Rare Entity	Valentina Andreasi	Stefano Partelli	San Raffaele Scientific Institute	33481
C-49	Differential Expression of GLUT-1 and FASN Across Histological Grades of Pancreatic Neuroendocrine Neoplasms	Erika Egal	PhD	Huntsman Cancer Institute at the University of Utah	33489
C-50	Preoperative Predictors of New-Onset Diabetes Mellitus Following Distal Pancreatectomy for Non-functioning Pancreatic Neuroendocrine Tumours	Stefano Partelli	MD, PhD	IRCCS San Raffaele Institute	33477

## Category 6: Population Science

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
P-1	Quality of Life and Care Experiences in a U.S. Multi-Institutional Neuroendocrine Tumor Cohort	Michael O'Rorke	PhD	University of Iowa	33433

## Category 6: Population Science

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
P-2	Racial and ethnic disparities in US neuroendocrine tumor clinical trial enrollment over the past quarter century.	Xena Zheng	MD	University of Miami/Jackson Memorial Hospital	33487
P-3	Higher composite Social Determinants of Health scores predict worsened survival for early-stage small bowel Neuroendocrine Tumors	Ahmed Alnajjar	MD, MSPH	University of Miami	33056
P-4	Survival of colorectal small cell carcinoma and comparison with colorectal adenocarcinoma	Nora Yanyi Sun	AB	Harvard University	33434
P-5	Treatment Decision Concerns: A Latent Class Analysis in Young-Onset Neuroendocrine Tumors	Tao Xu	PhD	University of Iowa	33435
P-6	Contemporary epidemiology of gastro-entero-pancreatic neuroendocrine neoplasms	Julie Hallet	MD, MSc, FRCSC, FSSO	University of Toronto	33436
P-7	Germline Pathogenic Variants Among Participants with Neuroendocrine Tumors in the Healthy Nevada Project	Katharine Thomas	MD	Renown Health, Pennington Cancer Institute; University of Nevada, School of Medicine	33443
P-8	Clinical details of early-onset neuroendocrine neoplasms differ by race and ethnicity and overall differ from typical-onset	Alan Paciorek	BS	University of California San Francisco	33485
P-9	Demographic and Survival Outcomes in Early-Onset Pancreatic Neuroendocrine Tumors: A National Cancer Database Study	Eugene Nwankwo	MD, MS	Mayo Clinic Rochester	33486
P-10	Racial and Gender Disparities in Neuroendocrine Tumors – A Retrospective Study Using a Single Institutional Database	Victoria Chung	DO	UT Southwestern	33677

## Category 7: Other

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
O-1	Distinct Sociodemographic, Symptom, and HRQoL Profiles in Early-Onset Neuroendocrine Tumors: Insights from the NET-PRO Study	Udhayvir Grewal	MD	Winship Cancer Institute of Emory University	33490
O-2	Analysis of patient selection for germline testing in early-onset gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) at a single institution	Lizeth Estrada		UCSF School of Medicine	33483
O-3	Clinical Features and Outcomes of Small and Very Small Pancreatic Neuroendocrine Tumors	Jad AbiMansour	MD	Mayo Clinic	33406
O-4	Real World Outcomes with Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas	Rushabh Gujarathi	MBBS	University of Louisville	33419
O-5	Recurrent Tympanic Paragangliomas: An Overview of Institutional Experience	Bonita Bennett	BSN, RN	University of Pennsylvania	33438
O-6	Effect of GLP-1 receptors agonists on progression free survival in patients with well differentiated neuroendocrine tumors treated with lanreotide.	Richard Vaca	MD	Icahn School of Medicine at Mount Sinai	33442
O-7	Treatment Sequence in Advanced Small Bowel Neuroendocrine Neoplasms: A Simulation Study	Nikolaos Trikalinos	MD	Washington University in St Louis	33452
O-8	Symptom burden and outcomes among patients with early-onset and average-onset neuroendocrine neoplasms.	Suriya Baskar	MD	The Brooklyn Hospital Center	33465
O-9	Neuroendocrine neoplasms diagnosed in the setting of inflammatory bowel disease: An appraisal of published literature and proposed management algorithm.	Nikolaos Trikalinos	MD	Washington University in St Louis	33470
O-10	Expanding Access to Neuroendocrine Tumor Care: Early Impact of the University of Utah NET Destination Care Program	Heloisa Soares	MD, PhD	University of Utah	33484

## Category 7: Other

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
O-11	Preventing Early Bioprosthetic Valve Deterioration in Carcinoid Heart Disease: A Case Series and Perioperative Management Strategy	Cezar A. Iliescu	MD, FACC, FSCAI	MD Anderson Cancer Center	33497
O-12	Molecular and Clinical Profiling of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Analysis of the Oncology Research Information Exchange Network Database	Benjamin Ueberroth	MD	University of Colorado Anschutz School of Medicine	33678
O-13	Peculiar Prostate Peculiarity: Exploring Ectopic Cushing's Disease in Prostate Neuroendocrine Carcinoma	Advith Suresh	MD	Howard University Hospital	33679

## Category 8: Trials in Progress

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
T-1	NETTER-3: [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, Grade 1/2 (Ki-67 <10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden	Pamela Kunz	MD	Yale Cancer Center	33272
T-2	STELLAR-311: A randomized phase 2/3 study of zanzalintinib versus everolimus in patients with previously treated advanced neuroendocrine tumors	Jaume Capdevila Castillon	MD, PhD	Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology	33270
T-3	Obixtamig (BI 764532) in relapsed/refractory delta-like ligand 3 (DLL3)-high extrapulmonary neuroendocrine carcinoma: Phase II DAREON®-5 dose-expansion trial in progress	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33389

## Category 8: Trials in Progress

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
T-4	CAREFNDR: Phase 3, Randomized, Placebo-Controlled Study of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33408
T-5	Trial in progress: A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants with DLL3 positive Neuroendocrine Carcinomas (NECs) and other Selected Solid Tumors	Huadong He	MS	Zai Lab	33422
T-6	Multicenter Phase 2 Trial of Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors: interim report	Michael Soulen	MD, FSIR, FCIRSE	Abramson Cancer Center University of Pennsylvania	33445
T-7	Trial-in-Progress: A Phase 2 Study of ONC206 in Patients with Advanced Pheochromocytoma and Paraganglioma	Meghan Sullivan	PhD, CMPP	Chimerix, Inc	33447
T-8	NCI 10479: A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lu 177 Dotatate in SSTR+ Pancreatic Neuroendocrine Tumors	Nikolaos Trikalinos	MD	Washington University in St Louis	33450
T-9	Alliance A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor-Positive Bronchial Neuroendocrine Tumors	Thomas Hope	MD	University of California San Francisco	33456
T-10	NET RETREAT: a CCTG-SWOG Phase II Study of 177Lutetium-Dotatate Retreatment vs. Standard of Care in Metastatic GEPNET Patients.	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33462

## Category 8: Trials in Progress

Poster #	Title	Presenter Name	Credentials	Organization	Abstract ID
T-11	A Phase 1 Trial of the Oncolytic Virus SVV-001 with Nivolumab and Ipilimumab in Patients with High Grade Neuroendocrine Neoplasms.	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33468
T-12	A Prospective Observational Study of GLP-1 and GLP-1/GIP Receptor Agonists in Patients with Well-Differentiated Neuroendocrine Tumors	Aaron Pruitt	MD	University of Kentucky Markey Cancer Center	33472
T-13	Stratification of Biochemical Response to Somatostatin Analogs in Carcinoid Syndrome: Implications for Risk of Carcinoid Heart Disease	Cezar A. Iliescu	MD	MD Anderson Cancer Center	33499
T-14	First-in-Human Study of a Novel Nonpeptide Drug Conjugate (CRN09682) in Patients With Somatostatin Receptor 2-Expressing Tumors	Daneng Li	MD	City of Hope	33397
T-15	ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.	Aman Chauhan	MD	University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center	33464

**NANETS**   
NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY  
[NANETS.NET](http://NANETS.NET)

